NCT04044768 2026-02-06
Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
USWM, LLC (dba US WorldMeds)
Phase 2 Active not recruiting
Clinical Trials
9 trialsNCT04526509 2024-11-26
Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors
Adaptimmune
Phase 1 Terminated
NCT05943990 2024-11-13
Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
Adaptimmune
Phase 1 Terminated
NCT06048705 2024-11-13
Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer
Adaptimmune
Phase 1 Terminated
NCT03063632 2023-10-25
Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT02992743 2023-04-11
Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma
GlaxoSmithKline
Phase 2 Completed
NCT02609984 2020-07-07
IMDZ-C232
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2 Terminated
NCT01957709 2019-07-10
Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma
Fred Hutchinson Cancer Center
Phase EARLY_PHASE1 Terminated
NCT00579501 2014-05-07
Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed